Voltage-gated L-type calcium channel subunit alpha-1C (Cav1.2) (Cav1.2)

Voltage-gated L-type calcium channels (LTCCs), primarily the Cav1.2 isoform, are essential transmembrane proteins in vascular smooth muscle cells that regulate vascular tone and systemic blood pressure [1, 7, 10]. These channels open in response to membrane depolarization, allowing an influx of extracellular calcium ions that triggers the contractile machinery of the smooth muscle, leading to vasoconstriction [3, 6, 13]. In the cardiovascular system, LTCCs are the primary therapeutic target for calcium channel blockers (CCBs), which are widely used to treat hypertension, angina pectoris, and certain arrhythmias [2, 5, 12]. By inhibiting calcium entry, these drugs promote vasodilation and reduce cardiac workload, thereby lowering blood pressure and improving myocardial oxygen supply [4, 8, 19]. While T-type calcium channels (e.g., Cav3.1, Cav3.2) also exist in vascular smooth muscle and contribute to myogenic tone and cell proliferation, the L-type channel remains the dominant target for clinical intervention [11, 14, 15]. Dysregulation of these channels is implicated in various pathologies, including hypertensive crises and cerebral vasospasms following subarachnoid hemorrhage [16, 17, 20]. The Cav1.2 subunit is also expressed in cardiac myocytes, where it mediates the plateau phase of the action potential and triggers contraction [12, 21]. Pharmacological modulation of these channels requires careful consideration of tissue selectivity to avoid adverse effects like excessive bradycardia or peripheral edema [5, 12].

Other names

L-type voltage-gated calcium channelVoltage-dependent L-type calcium channelLTCCCalcium channel L-type alpha-1C subunitCACNA1CDihydropyridine receptorVoltage-dependent calcium channels in vascular smooth muscle

Calcium channel blockers (CCBs) inhibit the influx of calcium ions through L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes. By binding to the alpha-1 subunit (Cav1.2), these drugs prevent the opening of the channel pore during membrane depolarization, thereby reducing intracellular calcium levels. This leads to relaxation of vascular smooth muscle (vasodilation), decreased peripheral resistance, and reduced myocardial contractility and heart rate (depending on the drug class).